Praktyka Lekarska Ewa Krzyzagorska

Poznan 61-655

1 studies enrolling now · 13 studies all time

What they study most

Atherosclerosis, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Diseases, Chronic Kidney Disease (CKD), Diabetes Mellitus, Type 2, Diabetes, Type 2, Diabetic Cardiomyopathies, Dyslipidemia, Gout, High Cardiovascular Risk, Hypertriglyceridemia

Studies at this site

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — Running, not enrolling
• Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Running, not enrolling
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia — Completed
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria — Completed
• Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function — Completed
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment — Completed
• A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment — Stopped early
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) — Completed